Clinical presentation and pulmonary function tests in
post-acute COVID-19 patients

GENZOR, Samuel, Petr JAKUBEC, Milan SOVA, Jan MIZERA, Pavol JOPPA, Radim BURGET and Pavol POBEHA. Clinical presentation and pulmonary function tests in post-acute COVID-19 patients. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2023, vol. 167, No 2, p. 185-191. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2022.039.

Other formats: BibTeX LaTeX RIS

TY  - JOUR
ID  - 2228641
AU  - Genzor, Samuel - Jakubec, Petr - Sova, Milan - Mizera, Jan - Joppa, Pavol - Burget, Radim - Pobeha, Pavol
PY  - 2023
TI  - Clinical presentation and pulmonary function tests in post-acute COVID-19 patients
JF  - Biomedical Papers, Olomouc: Palacky University
VL  - 167
IS  - 2
SP  - 185-191
EP  - 185-191
PB  - Palacky University
SN  - 12138118
KW  - COVID-19
KW  - post-acute phase
KW  - clinical presentation
KW  - pulmonary function tests
UR  - https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3264
N2  - Aims. The study analysed post-acute COVID-19 symptoms and the pulmonary function test (PFT) results in patients surviving the native strain of the virus. Methods. The study was prospective; the inclusion criteria were positive PCR test for SARS-CoV-2 and age 18-100. Exclusion criteria were active respiratory infection, known or suspicious pre-existing pulmonary disease, cardiac failure, recent or acute pulmonary embolism, anaemia, and neuromuscular diseases. The recruitment period was 1st March 2020 - 25th December 2020. The initial examination was performed 4-12 weeks after the disease onset. All subjects underwent physical examination, anamnesis, chest x-ray and PFT. Results. The study involved 785 subjects (345 male) mean age 53.8 (SD 14.6). The disease severity groups were: mild (G1), moderate (G2) and severe/critical (G3). Anosmia was present in the acute disease phase in 45.2% of G1 patients, but only in 4.5% of G3 patients. Dyspnoea occurred frequently in more severe groups (40%, 51.8% and 63.7% for G1, G2 and G3 respectively), while cough and fatigue showed no relationship to disease severity. Females were more likely to experience persistent symptoms. PFT results were significantly decreased in more severe groups compared to the mild COVID-19 patients, diffusing capacity was 86.3%, 79% and 68% of predicted values in G1, G2 and G3 respectively. Conclusion. Anosmia during the acute phase was associated with mild disease, persisting dyspnoea was more frequent after more severe COVID-19. Females tended to have persisting symptoms in post-acute phase more frequently. PFT results showed decrease with disease severity.
ER  -

Basic information
Original name	Clinical presentation and pulmonary function tests in post-acute COVID-19 patients
Authors	GENZOR, Samuel (203 Czech Republic), Petr JAKUBEC (203 Czech Republic), Milan SOVA (203 Czech Republic, belonging to the institution), Jan MIZERA (203 Czech Republic), Pavol JOPPA (703 Slovakia), Radim BURGET (203 Czech Republic) and Pavol POBEHA (703 Slovakia).
Edition	Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2023, 1213-8118.

Other information
Original language	English
Type of outcome	Article in a journal
Field of Study	30203 Respiratory systems
Country of publisher	Czech Republic
Confidentiality degree	is not subject to a state or trade secret
WWW	URL
Impact factor	Impact factor: 0.900 in 2022
RIV identification code	RIV/00216224:14110/23:00130052
Organization unit	Faculty of Medicine
Doi	http://dx.doi.org/10.5507/bp.2022.039
UT WoS	000863250600001
Keywords in English	COVID-19; post-acute phase; clinical presentation; pulmonary function tests
Tags	14110215, rivok
Tags	International impact, Reviewed
Changed by	Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 26/1/2024 10:18.

Abstract

Aims. The study analysed post-acute COVID-19 symptoms and the pulmonary function test (PFT) results in patients surviving the native strain of the virus. Methods. The study was prospective; the inclusion criteria were positive PCR test for SARS-CoV-2 and age 18-100. Exclusion criteria were active respiratory infection, known or suspicious pre-existing pulmonary disease, cardiac failure, recent or acute pulmonary embolism, anaemia, and neuromuscular diseases. The recruitment period was 1st March 2020 - 25th December 2020. The initial examination was performed 4-12 weeks after the disease onset. All subjects underwent physical examination, anamnesis, chest x-ray and PFT. Results. The study involved 785 subjects (345 male) mean age 53.8 (SD 14.6). The disease severity groups were: mild (G1), moderate (G2) and severe/critical (G3). Anosmia was present in the acute disease phase in 45.2% of G1 patients, but only in 4.5% of G3 patients. Dyspnoea occurred frequently in more severe groups (40%, 51.8% and 63.7% for G1, G2 and G3 respectively), while cough and fatigue showed no relationship to disease severity. Females were more likely to experience persistent symptoms. PFT results were significantly decreased in more severe groups compared to the mild COVID-19 patients, diffusing capacity was 86.3%, 79% and 68% of predicted values in G1, G2 and G3 respectively. Conclusion. Anosmia during the acute phase was associated with mild disease, persisting dyspnoea was more frequent after more severe COVID-19. Females tended to have persisting symptoms in post-acute phase more frequently. PFT results showed decrease with disease severity.

PrintDisplayed: 6/7/2024 07:17

Clinical presentation and pulmonary function tests in post-acute COVID-19 patients

Other applications